Who are FluMist, Influenza Virus Vaccine Live's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FluMist Quadrivalent (2017-2018), FluMist trivalent (2015-2016), Intranasal Influenza Live Attenuated Vaccine, Liquid CAIV-T, CAIV-T or TIV, CAIV-T, Liquid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flumist-influenza-virus-vaccine-live.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

FluMist, Influenza Virus Vaccine Live — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FluMist, Influenza Virus Vaccine Live (FluMist, Influenza Virus Vaccine Live) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated influenza vaccine. Area: Immunology.

phase 2 Live attenuated influenza vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

FluMist, Influenza Virus Vaccine Live (FluMist, Influenza Virus Vaccine Live) — MedImmune LLC. FluMist is a live attenuated influenza vaccine that replicates in the nasal mucosa to stimulate local and systemic immune responses against influenza viruses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FluMist, Influenza Virus Vaccine Live TARGET	FluMist, Influenza Virus Vaccine Live	MedImmune LLC	phase 2	Live attenuated influenza vaccine
FluMist Quadrivalent (2017-2018)	FluMist Quadrivalent (2017-2018)	MedImmune LLC	marketed	Live attenuated influenza vaccine (LAIV)	Influenza virus
FluMist trivalent (2015-2016)	FluMist trivalent (2015-2016)	MedImmune LLC	marketed	Live attenuated influenza vaccine
Intranasal Influenza Live Attenuated Vaccine	Intranasal Influenza Live Attenuated Vaccine	Jiangsu Province Centers for Disease Control and Prevention	marketed	Live attenuated influenza vaccine
Liquid CAIV-T	Liquid CAIV-T	MedImmune LLC	phase 3	Live attenuated influenza vaccine (LAIV)	Influenza A and B viral surface antigens (hemagglutinin and neuraminidase)
CAIV-T or TIV	CAIV-T or TIV	MedImmune LLC	phase 3	Live attenuated influenza vaccine (LAIV)
CAIV-T, Liquid	CAIV-T, Liquid	MedImmune LLC	phase 3	Live attenuated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated influenza vaccine class)

MedImmune LLC · 5 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FluMist, Influenza Virus Vaccine Live — Competitive Intelligence Brief. https://druglandscape.com/ci/flumist-influenza-virus-vaccine-live. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab